Financial Performance - The company's operating revenue for 2020 was approximately ¥706.30 million, a decrease of 23.61% compared to ¥924.54 million in 2019[16]. - The net profit attributable to shareholders for 2020 was approximately ¥55.23 million, down 43.21% from ¥97.26 million in 2019[16]. - The net cash flow from operating activities was approximately ¥73.39 million, a decline of 24.56% from ¥97.28 million in 2019[16]. - The basic earnings per share for 2020 was ¥0.4603, a decrease of 43.21% compared to ¥0.8105 in 2019[16]. - The total assets at the end of 2020 were approximately ¥906.52 million, an increase of 4.30% from ¥869.18 million at the end of 2019[16]. - The net assets attributable to shareholders at the end of 2020 were approximately ¥679.77 million, up 3.93% from ¥654.08 million at the end of 2019[16]. - The company reported a weighted average return on equity of 8.34% for 2020, down from 15.85% in 2019[16]. - The net profit after deducting non-recurring gains and losses for 2020 was approximately ¥53.04 million, a decrease of 44.29% from ¥95.21 million in 2019[16]. - The company reported a total of CNY 4,345.7 million in raised funds, with CNY 172 million allocated for various projects[90]. Dividend Distribution - The company plans to distribute a cash dividend of ¥1.25 per 10 shares, based on a total of 120 million shares[5]. - The cash dividend for 2020 represents 27.16% of the net profit attributable to the company's ordinary shareholders, which was approximately 55.23 million CNY[122]. - The total distributable profit for 2020 was approximately 300.74 million CNY, with the entire cash dividend amounting to 15 million CNY[119]. - The company distributed cash dividends of RMB 2.50 per 10 shares, totaling RMB 30 million for the 2019 fiscal year[116]. - The cash dividend payout ratio for 2020 is the lowest since 2018, reflecting a strategic decision to retain more earnings for future investments[120]. Market and Product Development - The company reported a total of 68 drug approval numbers, with major products included in the 2019 National Medical Insurance Directory, indicating a strong product portfolio[25]. - The main products include Torasemide injection, Tigecycline injection, and Cefoperazone sodium injection, which are positioned in high-demand therapeutic areas[25][26][27]. - The company has developed a freeze-dried powder injection process for Torasemide, significantly improving its solubility and stability, leading to its inclusion in multiple clinical treatment guidelines[31]. - The company is focusing on the transformation from generic drugs to innovative drugs, with a clinical candidate compound delivered by NMS Group in December 2020[44]. - The company plans to complete the registration application for several new drugs, including Propofol and Febuxostat, in 2021[43]. Research and Development - The company has established a comprehensive R&D system, participating in over 20 national and provincial technology projects, enhancing its innovation capabilities[34]. - The company has submitted three invention patent applications, strengthening its intellectual property protection and enhancing core competitiveness[43]. - The company is focusing on improving R&D capabilities and has initiated consistency evaluations for its main products to mitigate risks associated with regulatory compliance[112]. - The company aims to optimize its R&D project selection and enhance the depth and breadth of its research pipeline[109]. Operational Challenges and Risks - The company highlighted risks including industry policy changes and R&D risks in its future outlook[5]. - The company's revenue and net profit declined due to the impact of the pandemic, with a need to accelerate product structure transformation and innovation drug promotion[29]. - The company has implemented a comprehensive risk management strategy to address potential policy changes in the pharmaceutical industry[108]. Strategic Initiatives - The company acquired 90% of NMS Group, Italy's largest oncology drug R&D institution, enhancing its innovative drug development capabilities[38]. - The company is focusing on expanding its sales channels and enhancing brand recognition through academic promotions and training[47]. - The company aims to enhance its production capacity and market expansion through new construction projects and strategic investments[50]. - The company plans to enhance R&D efficiency and innovation, focusing on both generic and innovative drug development[104]. Shareholder and Governance Matters - The company has a robust governance structure in place to ensure compliance with cash dividend policies and protect shareholder interests[118]. - The company aims to protect the rights of shareholders, especially minority shareholders, through these measures[127]. - The company has established clear guidelines for share reduction pricing, ensuring it does not fall below the IPO price[148]. - The company has committed to avoiding any non-transactional fund exchanges with its subsidiaries during the period of being recognized as the actual controller[161]. Financial Management - The company reported a significant increase in investment activity cash outflow by 113.33% to ¥182,102,842.77[76]. - The company has maintained a focus on improving corporate governance and investor relations during the reporting period[55]. - The company has engaged Tianheng Accounting Firm for auditing services with a fee of 600,000 RMB[180]. - The company has not encountered any significant changes in the investment projects or their expected benefits[92].

南京海辰药业股份有限公司 2020 年第三季度报告全文 南京海辰药业股份有限公司 2020 年第三季度报告 2020-038 2020 年 10 月 1 南京海辰药业股份有限公司 2020 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人曹于平、主管会计工作负责人刘清华及会计机构负责人(会计主 管人员)吴国锋声明：保证季度报告中财务报表的真实、准确、完整。 2 南京海辰药业股份有限公司 2020 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | | 本报告期 | 年初至报告期末 | | | --- | --- | --- | --- | | 支付的优先股股利 | 0.00 | | 0.00 | | 用最新股本计算的全面摊薄每股收益（元/股） | 0.0988 | | 0.4028 | 非经常性损益项目和金额 √ 适用 □ 不适用 单位：元 | 项目 ...

南京海辰药业股份有限公司 2020 年半年度报告全文 南京海辰药业股份有限公司 2020 年半年度报告 2020-029 2020 年 08 月 1 南京海辰药业股份有限公司 2020 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司负责人曹于平、主管会计工作负责人刘清华及会计机构负责人(会计主 管人员)吴国锋声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告如涉及未来计划等前瞻性陈述，不构成公司对投资者实质承诺，投 资者及相关人士均应当对此保持足够的风险认识，并且应当理解计划、预测与 承诺之间的差异。 本公司请投资者认真阅读本半年度报告全文，并特别注意下列风险因素： 1、行业政策变化风险。公司所处的医药行业受行业政策变化影响较大，近 年来，随着医药体制改革不断深入，相关政策法规体系正在进一步修订和完善。 药品审批、质量监管、药品招标、公立医院改革、医保控费、两票制、药品集 中带量采购等一系列政策措 ...

Financial Performance - Total revenue for Q1 2020 was ¥166,174,066.04, a decrease of 21.09% compared to ¥210,599,993.07 in the same period last year[7] - Net profit attributable to shareholders was ¥17,167,277.16, down 22.91% from ¥22,269,622.00 year-on-year[7] - Basic earnings per share decreased by 22.90% to ¥0.1431 from ¥0.1856 in the previous year[7] - The total sales revenue from the top five customers was ¥25,562,189.78, accounting for 15.38% of total revenue, compared to 14.22% in the same period last year[22] - The total comprehensive income for the first quarter was CNY 16,990,242.10, compared to CNY 21,257,332.57 in the previous period, indicating a decrease of approximately 20.7%[49] Cash Flow - The net cash flow from operating activities was negative at -¥9,632,384.35, a decline of 1,763.38% compared to ¥579,083.91 in the same period last year[7] - Cash inflow from operating activities was CNY 157,384,675.64, down from CNY 216,823,068.80, reflecting a decline of about 27.4%[51] - The net cash flow from operating activities was negative at CNY -9,632,384.35, compared to a positive CNY 579,083.91 in the previous period[52] - Cash inflow from financing activities was CNY 80,000,000.00, up from CNY 40,000,000.00, representing a 100% increase[53] - The net cash flow from financing activities was CNY 48,394,971.95, compared to a negative CNY -1,440,227.08 in the previous period, showing a significant turnaround[53] Assets and Liabilities - Total assets increased by 4.85% to ¥911,370,208.90 from ¥869,176,296.72 at the end of the previous year[7] - Total liabilities amounted to CNY 239,545,229.67, up from CNY 215,193,760.87, indicating an increase of approximately 11.3%[36] - The company's equity attributable to shareholders reached CNY 672,055,824.40, compared to CNY 654,082,357.93, showing an increase of about 2.7%[37] - Total liabilities increased to CNY 225,470,338.93 from CNY 199,906,407.26, indicating a rise in financial obligations[43] Shareholder Information - The largest shareholder, Cao Yuping, holds 42.08% of the shares, with a total of 50,491,306 shares, of which 37,868,479 are pledged[10] - The total number of ordinary shareholders at the end of the reporting period was 8,844[10] Operational Efficiency - The company's investment income decreased by 129.49% to -¥98,187.67 due to reduced investment returns[17] - The company's long-term borrowings increased to ¥50,054,166.67 during the reporting period[17] - The total operating costs decreased to CNY 147,309,456.75 from CNY 185,651,419.46, reflecting a cost reduction strategy[43] - Research and development expenses were CNY 8,649,695.90, down from CNY 11,878,045.72, reflecting a focus on cost management[43] Market and Product Performance - The sales revenue of the main product, injectable Torasemide, was ¥63.56 million, a year-on-year decrease of 28.19%[19] - The sales revenue of injectable Cefoperazone decreased by 56.35% to ¥13.86 million, with a sales volume decline of 59.73%[19] Future Outlook and Projects - The company has not made significant adjustments to its annual business plan during the reporting period, focusing on management enhancement and market expansion[23] - There were no significant changes in the feasibility of projects or any major risks affecting future operations reported[28] - The company has implemented new revenue and leasing standards starting in 2020, affecting the financial statements[57] - The company is implementing new revenue and leasing standards starting from 2020, which may affect future financial reporting and comparisons[63]

Financial Performance - The company's operating revenue for 2019 was approximately ¥924.54 million, representing a year-on-year increase of 29.87% compared to ¥711.91 million in 2018[16]. - The net profit attributable to shareholders for 2019 was approximately ¥97.26 million, an increase of 16.86% from ¥83.22 million in 2018[16]. - The net cash flow from operating activities for 2019 was approximately ¥97.28 million, up by 25.99% from ¥77.21 million in 2018[16]. - The basic earnings per share for 2019 was ¥0.8105, reflecting a growth of 16.87% compared to ¥0.6935 in 2018[16]. - The total assets at the end of 2019 amounted to approximately ¥869.18 million, a 9.44% increase from ¥794.19 million at the end of 2018[16]. - The net assets attributable to shareholders at the end of 2019 were approximately ¥654.08 million, up by 12.59% from ¥580.93 million at the end of 2018[16]. - The company reported a weighted average return on equity of 15.85% for 2019, an increase from 15.24% in 2018[16]. - The quarterly revenue for Q4 2019 was approximately ¥239.94 million, with a net profit of approximately ¥19.80 million[18]. - The company achieved a total revenue of 924.54 million yuan, representing a year-on-year growth of 29.87%[38]. - The net profit attributable to shareholders was 97.26 million yuan, reflecting a year-on-year increase of 16.86%[38]. Dividend Distribution - The company plans to distribute a cash dividend of ¥2.5 per 10 shares, totaling approximately ¥30 million based on 120 million shares[5]. - The cash dividend for 2019 represents 30.85% of the net profit attributable to ordinary shareholders, which is 97,258,207.81 yuan[115]. - In 2018, the company distributed a cash dividend of 2.00 yuan per 10 shares, totaling 24 million yuan, which was 28.84% of the net profit[115]. - The total distributable profit for 2019 was 281,871,527.61 yuan, with the entire cash dividend amounting to 30 million yuan accounting for 100% of the profit distribution[111]. - The company has maintained a consistent dividend policy over the past three years, with cash dividends paid in 2017, 2018, and 2019[113]. Product Development and Market Position - The company reported a total of 67 drug approval numbers, with major products included in the 2019 National Medical Insurance Directory[24]. - The market coverage of the main product, Torasemide injection, increased with a year-on-year sales growth of 20%[27]. - The company produced and sold various products, including Torasemide injection, Tigecycline injection, and Cefoperazone sodium injection, all of which are listed as Class B drugs in the National Medical Insurance Directory[24][25][26]. - The company has developed a unique lyophilized formulation for Torasemide, enhancing its solubility and stability, which has been included in multiple clinical treatment guidelines[30]. - The company has 67 approved drug varieties, covering essential medications across various therapeutic areas, ensuring compliance with national healthcare reforms[33]. - The company has successfully registered new products, including Changchun Xiting injection, and is advancing several projects through the regulatory approval process[38]. - Sales revenue for the core product Zetu (injection Torasemide) reached 360 million yuan, a year-on-year increase of 22.83%[44]. Research and Development - The company is actively pursuing innovative drug development, having invested in the acquisition of a 90% stake in Italy's NMS Group, a leading oncology research institution[35]. - The company has initiated BE trials for multiple key projects, including Dabigatran etexilate and Tenofovir fumarate[41]. - The company plans to maintain its focus on the development of new products and technologies, particularly in the antibiotic and diuretic segments[56]. - Research and development expenses increased by 20.37% to CNY 59.90 million, representing 6.48% of total revenue[70]. - The company is committed to improving its R&D capabilities and expanding its pipeline through strategic partnerships and acquisitions[103]. Operational Challenges and Risks - The company has identified key risks including industry policy changes, R&D risks, and operational management risks in its future outlook[5]. - The company faced challenges in the pharmaceutical manufacturing industry, including weak independent innovation capabilities and an unregulated market order[27][28]. - The company is facing risks from industry policy changes, particularly regarding drug pricing and procurement policies, and is committed to adhering to national regulations[102]. Environmental and Social Responsibility - The company emphasizes its commitment to social responsibility, focusing on the development of affordable medicines and contributing to society[158]. - The company has established a dedicated department for environmental protection, ensuring compliance with pollution discharge standards and regular training for employees[161]. - The wastewater treatment system has a design capacity of 40 tons per hour, effectively handling wastewater generated from production processes[164]. - The company reported no instances of exceeding wastewater discharge limits, with all treated wastewater meeting the required standards[164]. - The company organized 66 employees to participate in blood donation activities, contributing a total of 18,400 milliliters to support clinical medical needs[162]. Shareholder and Governance Matters - The company has established a governance structure to protect the interests of shareholders, particularly minority shareholders[158]. - The company has committed to fulfilling all public commitments made during its initial public offering and will accept supervision from regulatory bodies and the public[134]. - The company has included a new subsidiary, Anqing Huichen Pharmaceutical Co., Ltd., in its consolidated financial statements, bringing the total number of subsidiaries to three[138]. - The company has not reported any significant accounting policy changes or major accounting error corrections during the reporting period[137]. - The company has made commitments to protect the interests of small and medium shareholders and will ensure that executive compensation is linked to the execution of return measures[135].

南京海辰药业股份有限公司 2019 年第三季度报告全文 南京海辰药业股份有限公司 2019 年第三季度报告 2019-067 2019 年 10 月 1 南京海辰药业股份有限公司 2019 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人曹于平、主管会计工作负责人刘清华及会计机构负责人(会计主 管人员)李小卫声明：保证季度报告中财务报表的真实、准确、完整。 2 南京海辰药业股份有限公司 2019 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 830,505,691.39 | 794,188,695.90 | | 4.57% | | 归属于上市公司股东的净资产 | 634,477 ...

南京海辰药业股份有限公司 2019 年半年度报告全文 南京海辰药业股份有限公司 2019 年半年度报告 2019-042 2019 年 08 月 1 南京海辰药业股份有限公司 2019 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司负责人曹于平、主管会计工作负责人刘清华及会计机构负责人(会计主 管人员)李小卫声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告中如有涉及未来的计划、业绩预测等方面的内容，均不构成公司对 任何投资者及相关人士的承诺，投资者及相关人士均应对此保持足够的风险认 识，并且应当理解计划、预测与承诺之间的差异。 公司已在本报告中详细描述存在的主要风险，包括：药品质量风险、研发 项目未达预期的风险、药品招标降价风险、对外投资风险、经营管理风险、募 投项目实施风险等。详细内容请查阅本报告第四节"经营情况讨论与分析"中"公 司面临的风险和应对措施"。 公司计划不派发现金红利，不送红股， ...

南京海辰药业股份有限公司 2019 年第一季度报告全文 南京海辰药业股份有限公司 2019 年第一季度报告 2019-016 2019 年 04 月 1 南京海辰药业股份有限公司 2019 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人曹于平、主管会计工作负责人刘清华及会计机构负责人(会计主 管人员)李小卫声明：保证季度报告中财务报表的真实、准确、完整。 2 南京海辰药业股份有限公司 2019 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 非经常性损益项目和金额 √ 适用 □ 不适用 单位：元 | 项目 | 年初至报告期期末金额 | 说明 | | --- | --- | --- | | 非流动资产处置损益（包括已计提资产减值准备的冲销部分） | -9,725.33 | | | 计入当期损益的政府补助（与企业业务密切相关，按照国家统 | 737,055.28 | | | 一标准定额或定量享 ...

南京海辰药业股份有限公司 2018 年年度报告全文 南京海辰药业股份有限公司 2018 年年度报告 2019-008 2019 年 03 月 1 南京海辰药业股份有限公司 2018 年年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 公司负责人曹于平、主管会计工作负责人刘清华及会计机构负责人(会计主 管人员)李小卫声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告中如有涉及未来的计划、业绩预测等方面的内容，均不构成公司对 任何投资者及相关人士的承诺，投资者及相关人士均应对此保持足够的风险认 识，并且应当理解计划、预测与承诺之间的差异。 公司已在本报告中详细描述存在的主要风险，包括：研发项目未达预期的 风险、药品招标降价风险、对外投资风险、经营管理风险、募投项目实施风险 等。详细内容请查阅本报告第四节"管理层讨论与分析"中"公司未来发展的展望 部分"。 公司经本次董事会审议通过的利润分配预案为：以 120，000，00 ...

南京海辰药业股份有限公司 2018 年第三季度报告全文 南京海辰药业股份有限公司 2018 年第三季度报告 2018-076 2018 年 10 月 1 南京海辰药业股份有限公司 2018 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人曹于平、主管会计工作负责人刘清华及会计机构负责人(会计主 管人员)李小卫声明：保证季度报告中财务报表的真实、准确、完整。 2 南京海辰药业股份有限公司 2018 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 √ 是 □ 否 追溯调整或重述原因 其他原因 | | 本报告期末 | 上年度末 | | 本报告期末比上年度 | | --- | --- | --- | --- | --- | | | | | | 末增减 | | | | 调整前 | 调整后 | 调整后 | | 总资产（元） | 738,915,822.83 | ...